02/05/2016 - By Blanver


As part of our growth strategy, we are proud to announce the acquisition of the CYG Biotech company, a Brazilian manufacturer of active pharmaceutical ingredients (APIs).

This acquisition consolidates our business, manufacturing excipients, finished dosage formulations and now also manufacturing APIs.

CYG’s industrial plant is located in Indaiatuba, 100 km from São Paulo city, 30 km from Campinas city and 10 km from Viracopos airport. It is a modern plant with cutting edge technology and has been in operation since 2010 and certified by ANVISA (Brazilian Regulatory Agency) to operate in this segment.

Operations and customer service will remain unchanged, conducted by the highest level of experienced professionals at CYG Biotech,  that have added much knowledge to our daily life.

We are in the process of integrating the business and our new members to Blanver’s family who are already an active part of our growth plans.

The new identity of this plant will be linked to the production of our pharmachemical products. Therefore, our excipients unit located in Itapevi known as Blanver Pharmachemical – Unit I and our new APIs manufacturing facility located in Indaiatuba becomes Blanver Pharmachemical – Unit II. The newly created Unit II will report directly to our General Manager Ricardo Grizzo.

The incorporation of CYG strengthens our position in the pharmaceutical industry, helping us to provide customer service and excellence in technical support to our customers around the world, and thus supporting us in our mission to develop, manufacture and market innovative products of high quality and competitiveness for the health and welfare of people.